BRPI1006134A2 - anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada. - Google Patents
anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.Info
- Publication number
- BRPI1006134A2 BRPI1006134A2 BRPI1006134A BRPI1006134A BRPI1006134A2 BR PI1006134 A2 BRPI1006134 A2 BR PI1006134A2 BR PI1006134 A BRPI1006134 A BR PI1006134A BR PI1006134 A BRPI1006134 A BR PI1006134A BR PI1006134 A2 BRPI1006134 A2 BR PI1006134A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- functional
- fragment
- polynucleotide
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009094613 | 2009-04-09 | ||
| PCT/JP2010/056294 WO2010117011A1 (ja) | 2009-04-09 | 2010-04-07 | 抗Siglec-15抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1006134A2 true BRPI1006134A2 (pt) | 2016-02-23 |
Family
ID=42936292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006134A BRPI1006134A2 (pt) | 2009-04-09 | 2010-04-07 | anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8575316B2 (pt) |
| EP (2) | EP2377932B1 (pt) |
| JP (2) | JP5653909B2 (pt) |
| KR (1) | KR101690340B1 (pt) |
| CN (2) | CN106317224B (pt) |
| AU (2) | AU2010235453B2 (pt) |
| BR (1) | BRPI1006134A2 (pt) |
| CA (1) | CA2750836C (pt) |
| CO (1) | CO6420359A2 (pt) |
| ES (1) | ES2840923T3 (pt) |
| IL (2) | IL213943A (pt) |
| MX (2) | MX343049B (pt) |
| MY (1) | MY152033A (pt) |
| NZ (2) | NZ605450A (pt) |
| RU (2) | RU2539790C2 (pt) |
| SG (2) | SG172419A1 (pt) |
| TW (1) | TWI468177B (pt) |
| WO (1) | WO2010117011A1 (pt) |
| ZA (1) | ZA201104545B (pt) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168181B2 (en) * | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| JP5173838B2 (ja) | 2006-02-13 | 2013-04-03 | アレシア・バイオセラピューティクス・インコーポレーテッド | 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列 |
| CN108130327A (zh) | 2007-10-11 | 2018-06-08 | 第三共株式会社 | 靶向破骨细胞相关蛋白Siglec-15的抗体 |
| EP2377932B1 (en) | 2009-04-09 | 2020-11-18 | Daiichi Sankyo Company, Limited | ANTI-Siglec-15 ANTIBODY |
| CA2813314A1 (en) | 2010-10-05 | 2012-04-12 | Daiichi Sankyo Company, Limited | Antibody targeting osteoclast-related protein siglec-15 |
| EP2753356B1 (en) * | 2011-09-09 | 2021-12-22 | Medimmune Limited | Anti-siglec-15 antibodies and uses thereof |
| JPWO2013147212A1 (ja) * | 2012-03-30 | 2015-12-14 | 第一三共株式会社 | 新規抗Siglec−15抗体 |
| US9464133B2 (en) | 2012-03-30 | 2016-10-11 | Daiichi Sankyo Company, Limited | CDR-modified anti-Siglec-15 antibody |
| AU2013293062A1 (en) * | 2012-07-19 | 2014-07-24 | Alethia Biotherapeutics Inc. | Anti-Siglec-15 antibodies |
| CA2925897A1 (en) | 2013-09-30 | 2015-04-02 | Daiichi Sankyo Company, Limited | Anti-lps o11 antibody |
| US20170129956A1 (en) * | 2014-06-18 | 2017-05-11 | Daiichi Sankyo Company, Limited | Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| KR102810368B1 (ko) | 2015-11-10 | 2025-05-19 | 예일 유니버시티 | 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법 |
| KR102644544B1 (ko) * | 2016-09-21 | 2024-03-11 | 넥스트큐어 인코포레이티드 | Siglec-15를 위한 항체 및 이의 사용 방법 |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| TWI782000B (zh) | 2017-03-30 | 2022-11-01 | 日商第一三共股份有限公司 | 抗gpr20抗體、其製造方法及其應用 |
| US20200115446A1 (en) | 2017-06-30 | 2020-04-16 | National University Corporation Hokkaido University | Pediatric osteoporosis drug that does not cause growth disorder |
| CA3071234A1 (en) | 2017-07-27 | 2019-01-31 | Daiichi Sankyo Company, Limited | Anti-cd147 antibody |
| CN118126182A (zh) | 2018-05-31 | 2024-06-04 | 第一三共株式会社 | 抗人tlr7抗体 |
| EP3831853A4 (en) | 2018-07-27 | 2022-06-01 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT |
| CN111378043B (zh) * | 2020-02-19 | 2021-02-09 | 南京医科大学 | 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用 |
| CN113817057B (zh) * | 2020-06-19 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种抗siglec15抗体及其应用 |
| CN112159475B (zh) * | 2020-10-10 | 2021-04-30 | 南京凯地生物科技有限公司 | Siglec-15单克隆抗体及其应用 |
| CN114525256A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用 |
| CN114437216A (zh) * | 2020-11-05 | 2022-05-06 | 上海津曼特生物科技有限公司 | 抗Siglec-15抗体及其在制备药物中的应用 |
| CN114591434B (zh) * | 2021-04-30 | 2023-02-28 | 杭州邦顺制药有限公司 | 抗Siglec15抗体及其制备方法和用途 |
| CN113577283A (zh) * | 2021-07-19 | 2021-11-02 | 河北医科大学第三医院 | Siglec-15抑制剂在制备防治骨巨细胞瘤药物中的应用 |
| CN114807052A (zh) * | 2022-06-07 | 2022-07-29 | 江苏亲科生物研究中心有限公司 | Siglec15单克隆抗体及其制备方法和用途 |
| CN117736324B (zh) * | 2022-09-22 | 2024-06-28 | 北京东方百泰生物科技股份有限公司 | 一种抗Siglec-15单克隆抗体的纯化方法 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN118878684B (zh) * | 2024-08-01 | 2025-10-21 | 中国人民解放军军事科学院军事医学研究院 | 抗唾液酸结合性免疫球蛋白样凝集素15的纳米抗体及其相关生物材料与应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| DE19653646A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
| JP3523650B2 (ja) | 1997-04-15 | 2004-04-26 | 三共株式会社 | 新規蛋白質及びその製造方法 |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US7608704B2 (en) | 2000-11-08 | 2009-10-27 | Incyte Corporation | Secreted proteins |
| EP1341812A2 (en) | 2000-11-08 | 2003-09-10 | Incyte Genomics, Inc. | Secreted proteins |
| WO2002064771A1 (fr) | 2001-02-15 | 2002-08-22 | Mochida Pharmaceutical Co., Ltd. | Nouvelle molecule d'adhesion cellulaire specifique de leucocyte active |
| TR201809678T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| US20050107588A1 (en) | 2001-11-13 | 2005-05-19 | Duggan Brendan M. | Receptors and membrane-associated proteins |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| AU2003243139B2 (en) | 2002-04-05 | 2007-06-21 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| EA013225B1 (ru) | 2003-01-07 | 2010-04-30 | Симфоген А/С | Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток |
| TWI359026B (en) | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
| US7405037B2 (en) | 2004-05-07 | 2008-07-29 | Lonza Walkersville, Inc. | Methods and tools for detecting collagen degradation |
| JP4604184B2 (ja) * | 2005-07-12 | 2010-12-22 | 独立行政法人産業技術総合研究所 | 新規糖鎖認識蛋白質及びその遺伝子 |
| JP5173838B2 (ja) | 2006-02-13 | 2013-04-03 | アレシア・バイオセラピューティクス・インコーポレーテッド | 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列 |
| US8168181B2 (en) * | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| CN108130327A (zh) | 2007-10-11 | 2018-06-08 | 第三共株式会社 | 靶向破骨细胞相关蛋白Siglec-15的抗体 |
| EP2377932B1 (en) | 2009-04-09 | 2020-11-18 | Daiichi Sankyo Company, Limited | ANTI-Siglec-15 ANTIBODY |
-
2010
- 2010-04-07 EP EP10761710.2A patent/EP2377932B1/en not_active Not-in-force
- 2010-04-07 ES ES10761710T patent/ES2840923T3/es active Active
- 2010-04-07 SG SG2011047412A patent/SG172419A1/en unknown
- 2010-04-07 MY MYPI2011002935 patent/MY152033A/en unknown
- 2010-04-07 RU RU2011128332/10A patent/RU2539790C2/ru active
- 2010-04-07 WO PCT/JP2010/056294 patent/WO2010117011A1/ja not_active Ceased
- 2010-04-07 KR KR1020117015666A patent/KR101690340B1/ko not_active Expired - Fee Related
- 2010-04-07 CA CA2750836A patent/CA2750836C/en active Active
- 2010-04-07 JP JP2011508375A patent/JP5653909B2/ja not_active Expired - Fee Related
- 2010-04-07 EP EP20165057.9A patent/EP3699277A1/en not_active Withdrawn
- 2010-04-07 BR BRPI1006134A patent/BRPI1006134A2/pt not_active Application Discontinuation
- 2010-04-07 NZ NZ605450A patent/NZ605450A/en not_active IP Right Cessation
- 2010-04-07 NZ NZ593550A patent/NZ593550A/xx not_active IP Right Cessation
- 2010-04-07 AU AU2010235453A patent/AU2010235453B2/en not_active Ceased
- 2010-04-07 SG SG10201401331TA patent/SG10201401331TA/en unknown
- 2010-04-07 US US13/143,253 patent/US8575316B2/en not_active Expired - Fee Related
- 2010-04-07 MX MX2014002553A patent/MX343049B/es unknown
- 2010-04-07 MX MX2011007342A patent/MX2011007342A/es active IP Right Grant
- 2010-04-07 CN CN201610749543.2A patent/CN106317224B/zh not_active Expired - Fee Related
- 2010-04-07 CN CN201080004195.7A patent/CN102272306B/zh not_active Expired - Fee Related
- 2010-04-08 TW TW99110882A patent/TWI468177B/zh not_active IP Right Cessation
-
2011
- 2011-06-20 ZA ZA2011/04545A patent/ZA201104545B/en unknown
- 2011-07-05 IL IL213943A patent/IL213943A/en active IP Right Grant
- 2011-07-08 CO CO11085127A patent/CO6420359A2/es active IP Right Grant
-
2013
- 2013-07-17 AU AU2013207589A patent/AU2013207589B2/en not_active Ceased
- 2013-09-30 US US14/041,479 patent/US9079959B2/en active Active
-
2014
- 2014-11-19 JP JP2014234461A patent/JP6210966B2/ja not_active Expired - Fee Related
- 2014-11-24 RU RU2014147188A patent/RU2014147188A/ru not_active Application Discontinuation
-
2015
- 2015-06-05 US US14/731,519 patent/US9751944B2/en not_active Expired - Fee Related
-
2017
- 2017-05-28 IL IL252561A patent/IL252561B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0919377A2 (pt) | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento | |
| BR112013008255A2 (pt) | anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo | |
| BR112012006326A2 (pt) | anticorpo biespecífico, composição farmacêutica, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira procariótica ou eucariótica e invenção | |
| BR112012022210A2 (pt) | anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado | |
| BRPI1007005A2 (pt) | anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6 | |
| BR112012024287A2 (pt) | anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira | |
| BRPI1005322A2 (pt) | anticorpo, composição farmacêutica e uso de pelo menos um anticorpo | |
| BRPI0909084A2 (pt) | Composição líquida, e, composto de peptídeo. | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| FR2943680B1 (fr) | Composition de caoutchoux et pneumatique utilisant cette composition. | |
| BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
| BR112014004168A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção | |
| UA113712C2 (xx) | Антитіло до fap і способи його застосування | |
| BRPI0912717A2 (pt) | Composição farmacêutica, e, uso de 5-azacitidina | |
| BRPI0914691A2 (pt) | composto imunoadjuvante, composição, uso de um composto imunoadjuvante, ácido nucléico, vetor recombinante, e, célula hospedeira | |
| BRPI0923199A2 (pt) | métodos e composições para detecção de anticorpos com fixação de complemento. | |
| IL230076A0 (en) | Certain chemical entities, compositions and methods | |
| BRPI0910557A2 (pt) | composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso. | |
| BRPI0909044A2 (pt) | anticorpo, sequência de ácidos nucleicos, vetor, composição farmacêutica, kit de partes, e, uso de um anticorpo, uma sequência de ácidos nucléicos, um vetor, uma composição farmacêutica ou um kit de partes | |
| BRPI0819299A2 (pt) | Uso de composição, e, composição contendo proteína | |
| BRPI0922106A2 (pt) | anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição | |
| BR112014016076A2 (pt) | peptídeo, vetor, contrução de peptídeo quimérico, ácido nucleico e uso dos mesmos e composição farmacêutica | |
| BR112015010817A8 (pt) | anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina | |
| BRPI0814420A2 (pt) | composição, e, uso de álcool alcoxilado. | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |